Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857502 · ClinicalTrials.gov registry record · Early Phase 1
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
A Early Phase 1 study of Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04857502: Recruiting Early Phase 1 study of Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
NCT04857502 is a Early Phase 1 study of Prostate Carcinoma and Recurrent Prostate Carcinoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04857502, a Early Phase 1 study of Prostate Carcinoma and Recurrent Prostate Carcinoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- DRUG 99mTc-based PSMA Imaging and Surgery Agent
- PROCEDURE Single Photon Emission Computed Tomography
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2027-06-01 |
| Phase | Early Phase 1 |
What NCT04857502 shows while recruiting
NCT04857502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.
NCT04857502 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04857502 about?
NCT04857502 is a clinical study titled "99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer". This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration o...
What is the current status of trial NCT04857502?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2021-04-27. Estimated completion is 2027-06-01.
What conditions does trial NCT04857502 study?
This clinical trial studies the following conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma.
What interventions are being tested in trial NCT04857502?
The interventions under investigation include: Computed Tomography (PROCEDURE), 99mTc-based PSMA Imaging and Surgery Agent (DRUG), Single Photon Emission Computed Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT04857502?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04857502 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04857502's enrollment target sits among peer trials
30 48th of 59 higher than 9 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
RECRUITING · Early Phase 1
-
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
ACTIVE NOT RECRUITING · Early Phase 1
-
An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
COMPLETED · Early Phase 1
-
Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
COMPLETED · Early Phase 1
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI